Han Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Han Zhou has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Lei Zhang
Department of Pharmaceutics China Pharmaceutical University Nanjing Jiangsu People's Republic of China
2 shared publications- Wenli Zhang
Department of Pharmaceutics, China Pharmaceutical University, Nanjing, Jiangsu 210009, PR China
2 shared publications Asly Chua An Wen
Department of Pharmaceutics, China Pharmaceutical University, Jiangsu, 210009, People’s Republic of China
1 shared publication- Bohui Xu
School of Pharmacy, Nantong University, Nantong 226019, P.R. China
1 shared publication Chunmeng Sun
Department of Pharmaceutics China Pharmaceutical University Nanjing Jiangsu People's Republic of China
1 shared publicationDada Wang
Jiangsu Agri-Animal Husbandry Vocational College, Taizhou, Jiangsu, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Wiley in Advanced Science
- p. e77714
Beyond Biomimetics: Pathology‐Informed Engineering Rescues Reconstituted HDL From Inflammatory Dysfunction for Sepsis Immunotherapy
Biomimetic therapies hold great promise for treating intractable diseases, yet their translation is often hindered by dysfunction—the loss of intended biological function upon exposure to pathological microenvironments. This challenge is well exemplified by reconstituted high‐density lipoprotein (rHDL), a clinically advanced HDL mimetic and representative biomimetic drug delivery platform. Here, guided by a pathology‐informed identification‐design‐evaluation‐validation workflow, we identified representative sepsis‐relevant dysfunction liabilities of HDL‐based systems under pathology‐relevant conditions and designed an adaptive engineered guard for inflammatory stress (AEGIS) strategy to rescue rHDL function. AEGIS integrates triphenylphosphine‐modified ceria nanozyme‐celastrol coordination complex (TCe–C) into rHDL to form TCe‐C@rHDL, enabling carrier protection, decoupling disease‐driven damage from dysfunction, and preserving HDL‐intrinsic routing for hierarchical cytoplasmic and mitochondrial delivery. Across multiple evaluation models, including inflammatory biochemical challenges, patient serum under shear flow, and inflammatory animal settings, TCe‐C@rHDL consistently preserved biomimetic function better than a clinical‐stage CER‐001 mimetic. This performance was further validated by therapeutic efficacy in vivo, restoring 90% survival in LPS‐induced systemic inflammation versus 40% for the CER‐001 mimetic, and improving survival to 80% in the CLP model when combined with antibiotics versus 40% for antibiotics alone. Collectively, this work establishes a paradigm for next‐generation biomimetic systems that remain functional under pathological stress.
- 10 September 2026
- Published by Wiley in Advanced Science
- p. e77714
Open AccessBeyond Biomimetics: Pathology‐Informed Engineering Rescues Reconstituted HDL From Inflammatory Dysfunction for Sepsis Immunotherapy
Biomimetic therapies hold great promise for treating intractable diseases, yet their translation is often hindered by dysfunction—the loss of intended biological function upon exposure to pathological microenvironments. This challenge is well exemplified by reconstituted high‐density lipoprotein (rHDL), a clinically advanced HDL mimetic and representative biomimetic drug delivery platform. Here, guided by a pathology‐informed identification‐design‐evaluation‐validation workflow, we identified representative sepsis‐relevant dysfunction liabilities of HDL‐based systems under pathology‐relevant conditions and designed an adaptive engineered guard for inflammatory stress (AEGIS) strategy to rescue rHDL function. AEGIS integrates triphenylphosphine‐modified ceria nanozyme‐celastrol coordination complex (TCe–C) into rHDL to form TCe‐C@rHDL, enabling carrier protection, decoupling disease‐driven damage from dysfunction, and preserving HDL‐intrinsic routing for hierarchical cytoplasmic and mitochondrial delivery. Across multiple evaluation models, including inflammatory biochemical challenges, patient serum under shear flow, and inflammatory animal settings, TCe‐C@rHDL consistently preserved biomimetic function better than a clinical‐stage CER‐001 mimetic. This performance was further validated by therapeutic efficacy in vivo, restoring 90% survival in LPS‐induced systemic inflammation versus 40% for the CER‐001 mimetic, and improving survival to 80% in the CLP model when combined with antibiotics versus 40% for antibiotics alone. Collectively, this work establishes a paradigm for next‐generation biomimetic systems that remain functional under pathological stress.
- Open Access
- 1 April 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 5377-5391
Combined Mulberry Leaf Polysaccharide-Caged Liposomes for Effective Oral Drug Delivery in Rat Model
Introduction: Mulberry leaf polysaccharide (MLP) has gained attention as a potential anti-diabetic agent for lowering blood glucose and improving insulin sensitivity. However, the low gastrointestinal stability and oral bioavailability limit its clinical application. To address this issue, a novel drug-caged liposomes (MLP-CL) was developed to enhance oral delivery efficiency of MLP compared to conventional drug-encapsulated liposomes (MLP-L). Methods: MLP-L and MLP-CL were prepared by the thin-film hydration method. Subsequently, the structural integrity of these liposomes was assessed via in vitro release test and confocal laser microscopy (CLSM) analysis. Madin-Darby canine kidney (MDCK) cells were employed to investigate the cellular uptake mechanisms and transcellular transport efficiency. Finally, the biodistribution profiles and transport mechanisms of liposomes were evaluated through in vivo fluorescence imaging and pharmacokinetic studies in Sprague Dawley rats. Results: Compared to MLP-L, which released 80% of MLP within 4 hours, MLP-CL showed sustained release with only 40% released in the same period. MLP-CL also enabled more effective co-delivery of MLP and liposomes to MDCK cells, indicating improved structural integrity and cellular uptake. Transcellular transport assay confirmed that MLP-CL was transported across cells more efficiently. In vivo, MLP-CL increased intestinal accumulation and raised plasma MLP concentration by 50%. Additionally, by comparing the discrepancy between the lymphatic-suppression model and the normal model, it was found that 63.56% of MLP-CL was absorbed through the lymphatic pathway compared to 18.05% for MLP-L. Conclusion: Compared to conventional MLP-L, conjugation of polysaccharide improves the structural integrity of MLP-CL in the gastrointestinal tract, which in turn improves lymphatic uptake and bioavailability. This provides an effective strategy for the design of polysaccharide delivery systems.
- 1 April 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 5377-5391
Open AccessCombined Mulberry Leaf Polysaccharide-Caged Liposomes for Effective Oral Drug Delivery in Rat Model
Introduction: Mulberry leaf polysaccharide (MLP) has gained attention as a potential anti-diabetic agent for lowering blood glucose and improving insulin sensitivity. However, the low gastrointestinal stability and oral bioavailability limit its clinical application. To address this issue, a novel drug-caged liposomes (MLP-CL) was developed to enhance oral delivery efficiency of MLP compared to conventional drug-encapsulated liposomes (MLP-L). Methods: MLP-L and MLP-CL were prepared by the thin-film hydration method. Subsequently, the structural integrity of these liposomes was assessed via in vitro release test and confocal laser microscopy (CLSM) analysis. Madin-Darby canine kidney (MDCK) cells were employed to investigate the cellular uptake mechanisms and transcellular transport efficiency. Finally, the biodistribution profiles and transport mechanisms of liposomes were evaluated through in vivo fluorescence imaging and pharmacokinetic studies in Sprague Dawley rats. Results: Compared to MLP-L, which released 80% of MLP within 4 hours, MLP-CL showed sustained release with only 40% released in the same period. MLP-CL also enabled more effective co-delivery of MLP and liposomes to MDCK cells, indicating improved structural integrity and cellular uptake. Transcellular transport assay confirmed that MLP-CL was transported across cells more efficiently. In vivo, MLP-CL increased intestinal accumulation and raised plasma MLP concentration by 50%. Additionally, by comparing the discrepancy between the lymphatic-suppression model and the normal model, it was found that 63.56% of MLP-CL was absorbed through the lymphatic pathway compared to 18.05% for MLP-L. Conclusion: Compared to conventional MLP-L, conjugation of polysaccharide improves the structural integrity of MLP-CL in the gastrointestinal tract, which in turn improves lymphatic uptake and bioavailability. This provides an effective strategy for the design of polysaccharide delivery systems.